CAR‑T is no universal miracle drug. It has well‑defined eligibility criteria, standardised workflows and controllable risks. Nor is it always a patient’s final therapeutic option; for many high‑risk haematology patients, it may represent the first step toward cure. Anxious patients are advised not to draw premature conclusions or give up hope. Bring your complete medical records for comprehensive assessment by an experienced CAR‑T team to identify the most suitable treatment

Should patients receive a transplant after CAR‑T‑induced remission? When is the optimal timing? Is there hope for a second transplant? Will TP53 gene mutation inevitably result in relapse? These are frequent questions raised by parents of children with hematologic malignancies. In this session, Director Li Zhihui from Beijing Boren Hospital answers these key concerns one by one.

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.